{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:24:49Z","timestamp":1761171889720,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.farma.2009.11.003","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T05:55:40Z","timestamp":1267077340000},"page":"204-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efectividad y seguridad de 5-azacitidina en tres pacientes con s\u00edndrome mielodispl\u00e1sico"],"prefix":"10.1016","volume":"34","author":[{"given":"M.C.","family":"Garz\u00e1s-Mart\u00edn de Almagro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.I.","family":"Gago S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Cuevas Asencio,","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reyes Malia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2009.11.003_bib1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199905273402107","article-title":"Myelodisplasia","volume":"340","author":"Heaney","year":"1999","journal-title":"N Engl J Hematol"},{"key":"10.1016\/j.farma.2009.11.003_bib2","first-page":"136","article-title":"Myelodysplastic syndromes","author":"Peter","year":"2002","journal-title":"American Society of Hematology Meeting"},{"key":"10.1016\/j.farma.2009.11.003_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00062752-200301000-00010","article-title":"Current challenges in therapy of myelodysplastic syndromes","volume":"10","author":"Estey","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.farma.2009.11.003_bib4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2146\/ajhp040385","article-title":"Azacitidine: A novel agent for myelodisplastic s\u00edndromes","volume":"62","author":"Sullivan","year":"2005","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.farma.2009.11.003_bib5","unstructured":"National Comprehensive Cancer Network. Practice guidelines in oncology: myelodysplastic syndromes v.2.2009 (http:\/\/www.nccn.org\/professionals\/physicians_gls\/PDF\/mds.pdf)."},{"key":"10.1016\/j.farma.2009.11.003_bib6","article-title":"Novel agents for the management of myelodysplastic s\u00edndromes","volume":"12","author":"Meletis","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.farma.2009.11.003_bib7","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial or azacitidine in patients whith the myelodysplastic syndromes: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2009.11.003_bib8","first-page":"A12","article-title":"Azacitidine (Aza C) in myelodysplastic syndromes (MSD), CALGB studies 8421 and 8921","volume":"68","author":"Silverman","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1016\/j.farma.2009.11.003_bib9","first-page":"816","article-title":"Low dose continous infusion azacytidine is an effective therapy for patients with myelodysplastic syndromes, a study of the Cancer and Leukemia Group B","volume":"116","author":"Silverman","year":"1990","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.farma.2009.11.003_bib10","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1517\/13543784.16.12.1967","article-title":"The role of azacitidine in the treatment of myelodysplastic syndromes","volume":"16","author":"Haifa Abdulhaq","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.farma.2009.11.003_bib11","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Versi\u00f3n 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http:\/\/www.ctep.cancer.gov). Publish Date: August 9, 2006."},{"key":"10.1016\/j.farma.2009.11.003_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: Azacitidine (5-Azacydtidine, Vidaza TM) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.farma.2009.11.003_bib13","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further of trials with azacitidine in patiens with myelodysplastic syndrome: studies 8421, 8921 and 9221 by the Cancer and Leukemia Group","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2009.11.003_bib14","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of Azacitidine of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B Study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2009.11.003_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634310000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634310000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:15:42Z","timestamp":1761106542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634310000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1130634310000322"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2009.11.003","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectividad y seguridad de 5-azacitidina en tres pacientes con s\u00edndrome mielodispl\u00e1sico","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2009.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 SEFH. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}